SecBot SecBot

OVID

Ovid Therapeutics Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001636651 Biotech & Drug Discovery
$2.17 +0.01 (+0.69%)
Oct 26 4:00 PM ET · prev $2.16
Market cap
$462.9M
Small cap
Consensus
Buy
94% Buy or better · 16 analysts
Median target
$5.00
+130% · range $4.00–9.00
Next earnings
Nov 11
in 16 days · EPS est. −$0.08
1 year
+35.9%
from $1.60 · Oct 27
30 days
−11.6%
from $2.46
52-week range
$1.20–2.96
−27% from high · low Nov 13
Avg volume 20D
1.68M
Oct 21 spike 5.00M
Short interest
18.95M
≈9.7% of shares · −10.4%
Days to cover
8.9
at average volume
Insider net
-$29.3K
0 buyers · 2 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read MIXED 1 report · 90 days
Balance 0 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/1 ·Next Earnings date, Nov 11, 2026
Strongest NEUTRAL Jeffrey A. Rona, an affiliated stockholder of Ovid Therapeutics, filed a Form 144 notice of intent to sell…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    2 insiders sold $29.3K.

  • InstitutionsBULLISH

    Q2 2026: 21 added (0 new), 8 trimmed or exited.

  • AnalystsBULLISH

    15 of 16 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.106 → −$0.084 over 90 days. 5 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest −10.4% to 18.95M shares. 8.9 days to cover, ≈9.7% of shares.

  • TrendDOWNTREND

    15% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.DOUBLED10,823,480$29.1M
STATE STREET CORPDOUBLED7,900,765$21.3M
VANGUARD CAPITAL MANAGEMENT LLCADD7,760,114$20.9M
FEDERATED HERMES, INC.ADD5,951,666$16.0M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED4,072,653$11.0M
Point72 Asset Management, L.P.ADD1,945,727$5.2M
NORTHERN TRUST CORPDOUBLED1,246,139$3.4M
VANGUARD FIDUCIARY TRUST COADD1,140,753$3.1M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

16 analysts
Buy 94% rate it Buy or better
Strong Buy7Buy8Hold1Sell0Strong Sell0
12-month targets · 10 analysts

Price is below the lowest target. Median implies +130%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 15, 2026Wolfe Research
INITIATE
INITIATEOutperform
Oct 9, 2026Cantor Fitzgerald
INITIATE
INITIATEOverweight
Oct 6, 2026Guggenheim
INITIATE
INITIATEBuy
Oct 5, 2026Guggenheim
INITIATE
INITIATEBuy
Sep 11, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Aug 3, 2026Oppenheimer
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$0
bought · 0 insiders
$29.3K
sold · 2 insiders
DateInsiderTypeValue
Jul 6, 2026
Carter Charles Ross
Chief Financial Officer
AWARD50,000 sh
Jun 15, 2026
Greka Anna
Director
AWARD130,000 sh
Apr 7, 2026
Fitzgerald Kevin Joseph
Director
AWARD$45.0K
Apr 7, 2026
Friedman Bart
Director
AWARD$22.5K
Apr 7, 2026
PAPADOPOULOS STELIOS
Director
AWARD$45.0K
Mar 23, 2026
LEVIN JEREMY M
Executive Chairman
EXERCISE$66.3K
Feb 26, 2026
Rona Jeffrey A
CBFO
AWARD68,125 sh
Feb 26, 2026
Rona Jeffrey A
CBFO
AWARD408,750 sh

Earnings setup

Estimates
Nov 11
reports in 16 days
−$0.08
EPS estimate, this quarter
+20%
estimate change, 90 days
5↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.08-$0.10–-$0.05+4.7%$26.3K
Next Q-$0.08-$0.11–$0.01+11.5%$75.8K
Current FY-$0.36-$0.41–-$0.24+3.2%$791.6K
Next FY-$0.37-$0.50–-$0.29+5.3%$325.6K

Short side

FINRA· Sep 30, 2026
18,948,082
shares short
-10.4%
vs prior settlement
8.9
days to cover
≈9.7%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 18, 2026 Earnings calendar
OVID Q2 2026 Earnings Scheduled — 2026-08-18
Aug 14, 2026 SEC
Jeffrey A. Rona, an affiliated stockholder of Ovid Therapeutics, filed a Form 144 notice of intent to sell up to…
144 — Impact 3/10
Jul 8, 2026 SEC
Ovid Therapeutics announced the departure of CFO Jeffery Rona by mutual agreement, effective July 6, 2026, with an…
8-K — Impact 2/10
Jul 6, 2026 Insider
Carter Charles Ross was granted 50,000 shares
Chief Financial Officer
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
10,823,480 shares ($29.1M)
Jun 30, 2026 Inst.
STATE STREET CORP — DOUBLED
7,900,765 shares ($21.3M)
Jun 15, 2026 Insider
Greka Anna was granted 130,000 shares
Director
Jun 3, 2026 SEC
Ovid Therapeutics appointed Dr. Anna Greka, a Harvard Medical School professor and Broad Institute executive, as a…
8-K — Impact 2/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
OVID Q3 2026 Earnings Scheduled — 2026-11-11
Recent
Aug 18, 2026
Earnings date
OVID Q2 2026 Earnings Scheduled — 2026-08-18
Aug 13, 2026
Earnings
Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better…
Jul 8, 2026
Press release
Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development
NEW YORK, July 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better…
Jun 30, 2026
Short interest
Short Interest: OVID up 86% to 22.0M shares
Settlement 2026-06-30 | Days to cover: 3.78 | ≈11.79% of shares outstanding (est.)
Jun 4, 2026
Press release
Ovid Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better…

SecBot reports

9 filings · 2 press releases · 1 bullish · 0 bearish · 1 mixed · 7 neutral
All OVID filing & press-release reports (11)